ReviewCancer control : journal of the Moffitt Cancer Center
Intraocular lymphoma: update on diagnosis and management.
Review in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 206 citations in OpenAlex.
- Aqueous humor biomarkers in ocular oncology: Insights and advances.Cell reports. Medicine · 2025Review
- Next-gen oncology: the role of CAR-T cells against ocular lymphoma and myeloma.Eye (London, England) · 2024Article
- Ophthalmic Manifestations in Patients with Blood Malignancies.Hematology reports · 2024Review
- Clinical Outcomes in Vitrectomized versus Non-vitrectomized Eyes in Patients with Primary Vitreoretinal Lymphoma.Ocular immunology and inflammation · 2023Observational
- Refractory Primary Vitreoretinal Lymphoma Involving the Spinal Cord with a Temporary Complete Response to Tirabrutinib.Internal medicine (Tokyo, Japan) · 2023Article
- Unilateral panuveitis secondary toBMJ case reports · 2022Article
- Update in Molecular Testing for Intraocular Lymphoma.Cancers · 2022Review
- A pilot study of the use of dynamic analysis of cell-free DNA from aqueous humor and vitreous fluid for the diagnosis and treatment monitoring of vitreoretinal lymphomas.Haematologica · 2022Article
- Advanced OCT Analysis of Biopsy-proven Vitreoretinal Lymphoma.American journal of ophthalmology · 2022Article
- Diagnostic Accuracy of Cell Block Preparations and Clinical Features Affecting It in Vitreoretinal Lymphoma.Journal of clinical medicine · 2022Article
- Challenges in the Diagnosis of Intraocular LymphomaTurkish journal of ophthalmology · 2021Article
- Article
- Pharmacokinetics and Toxicity Evaluation of a PLGA and Chitosan-Based Micro-Implant for Sustained Release of Methotrexate in Rabbit Vitreous.Pharmaceutics · 2021Article
- Identification of Prognostic Markers in Patients with Primary Vitreoretinal Lymphoma by Clustering Analysis Using Clinical Data.Journal of clinical medicine · 2020Article
- Systemic diffuse large B-cell lymphoma with bilateral ciliary body involvement.Chinese medical journal · 2020Article
- Cytologic and Molecular Diagnostics for Vitreoretinal Lymphoma: Current Approaches and Emerging Single-Cell Analyses.Frontiers in molecular biosciences · 2020Review
- A Review of Clinical Applications and Side Effects of Methotrexate in Ophthalmology.Journal of ophthalmology · 2020Review
- Intraocular Biopsy and ImmunoMolecular Pathology for "Unmasking" Intraocular Inflammatory Diseases.Journal of clinical medicine · 2019Review
- Primary vitreoretinal lymphoma: prevalence, impact, and management challenges.Clinical ophthalmology (Auckland, N.Z.) · 2019Review
- B-scan ultrasound and cytology of the vitreous in primary central nervous system lymphoma with vitreoretinal involvement.International journal of ophthalmology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
backgroundPrimary intraocular lymphoma (PIOL) is a subset of primary central nervous system lymphoma (PCNSL) in which lymphoma cells initially invade the retina, vitreous, or optic nerve head, with or without concomitant CNS involvement. The incidence of this previously rare condition has increased dramatically. Given its nonspecific presentation and aggressive course, PIOL provides a diagnostic and therapeutic challenge.
methodsWe review the current strategies for diagnosis and treatment of PIOL and present our own experience with PIOL.
resultsRecent developments in the diagnosis of PIOL include immunohistochemistry, flow cytometry, cytokine evaluation, and molecular analysis. However, definitive diagnosis still requires harvesting of tissue for histopathology. Optimal treatment for PIOL remains unclear. Initial therapeutic regimens should include methotrexate-based chemotherapy and radiotherapy to the brain and eye. In addition, promising results have been seen with intravitreal methotrexate and autologous stem cell transplantation for recurrent and refractory disease.
conclusionsEfforts to further determine the immunophenotype and molecular characteristics of PIOL will continue to assist in the diagnosis of PIOL. Future studies are required to determine the role of radiotherapy and optimal local and systemic chemotherapeutic regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.